Aug 19, 2020 | News, Regulatory
Gilead submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotnib, a treatment for rheumatoid arthritis, which the FDA rejected due to safety concerns, particular in the 200mg dose. “We are disappointed in this outcome and will...
May 11, 2020 | News, Regulatory
The FDA announced on Friday (5/8) of its approval for Eli Lily’s Retevmo, a drug which treats three kinds of tumors associated with lung and thyroid cancer: non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. This comes as...
Apr 20, 2020 | News, Regulatory
As part of an ongoing global study, MemorialCare Long Beach Center has administered the antiviral drug Remdesivir to three patients as a possible treatment for Covid. This news comes closely after Gilead, a biotech company based out of the California Bay Area,...
Jan 23, 2020 | News, Regulatory
On November 14, 2019, the U.S. Food and Drug Administration gave approval to BeiGene Ltd’s lymphoma treatment, Brukinsa. BeiGene is a Chinese biopharmaceutical company that focused on cancer treatments. The treatment “Brukinsa” has been tested on 118...
Jan 22, 2020 | News, Regulatory
What is NRDL? The National Reimbursement Drug List (NRDL) was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments. Between 2000 and 2017, the NRDL has been updated twice, but the reimbursement process is poor. The...
